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Abstract: Around 800,000 people worldwide die from suicide every year and it’s the 10th leading
cause of death in the US. It is of great value to build a mathematic model that can accurately predict
suicide especially in high-risk populations. Several different ML-based models were trained and
evaluated using features obtained from electronic medical records (EMRs). The contribution of each
feature was calculated to determine how it impacted the model predictions. The best-performing
model was selected for analysis and decomposition. Random forest showed the best performance
with true positive rates (TPR) and positive predictive values (PPV) of greater than 80%. The use of
Aripiprazole, Levomilnacipran, Sertraline, Tramadol, Fentanyl, or Fluoxetine, a diagnosis of autistic
disorder, schizophrenic disorder, or substance use disorder at the time of a diagnosis of both PTSD
and bipolar disorder, were strong indicators for no SREs within one year. The use of Trazodone and
Citalopram at baseline predicted the onset of SREs within one year. Additional features with potential
protective or hazardous effects for SREs were identified by the model. We constructed an ML-based
model that was successful in identifying patients in a subpopulation at high-risk for SREs within a
year of diagnosis of both PTSD and bipolar disorder. The model also provides feature decompositions
to guide mechanism studies. The validation of this model with additional EMR datasets will be of
great value in resource allocation and clinical decision making.
Keywords: PTSD; bipolar disorder; machine learning; random forest; suicide-related events;
model decomposition
1. Introduction
Approximately 800,000 people worldwide die from suicide every year [1]. Suicide is the 10th
leading cause of death in the United States, with 48,000 deaths occurring in 2018 [2]. Because the rate
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of suicide among all deaths has continued to increase since 1999 [2–8], reversing the suicide rate has
been prioritized by the World Health Organization [1].
Multiple studies have identified factors related to suicide. These factors include age, gender,
and alcohol abuse [9,10]. However, it is hard to quantify the influence of these factors using traditional
statistical methods [11–13]. With the rise of machine-learning (ML) algorithms, several successful
studies have predicted suicide risk based on different ML-based methods with good accuracy [14–17].
However, few studies have focused on risk factors among high-risk populations that may require
more intensive interventions to prevent suicides. Some research suggest that, among all mental
disorders, bipolar disorder contributes most to the risk for suicide [18]. This risk can be higher when
comorbidity exists with other psychiatric disorders [19]. Patients with bipolar disorder alternate
between manic and depressive episodes [20], leading to considerable impairment of life quality [21,22].
Approximately 1% of the worldwide population suffer from bipolar disorder [23,24].
Although considered a controversial suicide risk factor, post-traumatic stress disorder (PTSD) is
one of the most common comorbidities of bipolar disorder [25–27], with a lifetime comorbidity rate of
16%–39% [28]. PTSD is a trauma- and stressor-related disorder with the major post-trauma symptoms
being fear-based re-experiencing, anhedonia, dysphoric mood stages, or dissociative symptoms [29].
The lifetime prevalence of PTSD is 7.8% [30]. Among patients with bipolar disorder, the time spent
with illness as well as SREs (ideation, attempts, and deaths) are significantly higher in patients also
diagnosed with PTSD [27,31,32].
Suicide prevention strategies have been proven to substantially decrease the suicide rate [33–36].
The importance of recognizing depression and suicidal tendencies has been emphasized in several
reviews [33,35,37,38]. However, comprehensive suicide prevention programs consume time, labor,
and resources that limit the application of care to all patients with bipolar disorder and PTSD. A time-,
labor-, and resource-saving quantitative measurement for SREs in this high-risk population is needed
to guide clinical decision-making and to help distribute resources to the patients who can most benefit
from them.
An ML-based random forest model was constructed to identify and quantify risk factors that
induce suicide among patients diagnosed with both bipolar disorder and PTSD. Using factors extracted
from electronic medical records (EMRs) of patients with both diagnosis of bipolar disorder and PTSD,
patients with a higher risk of an SRE within a year were identified. The model focused primarily on
predictors like baseline disease conditions or pharmacy records which can be easily obtained and are
less likely to be biased by subjective factors. Extra emphasis was placed on lithium usage, as previous
studies have demonstrated that lithium was effective in preventing death by suicide in patients with
mental disorders [34,39,40].
2. Materials and Methods
2.1. Data Sources
Data was collected from the EMRs of patients seen at UPMC (University of Pittsburgh Medical
Center) facilities between 2004 and 2019. The cohort of patients with PTSD and bipolar disorders
were identified based on the International Classification of Diseases (ICD) 9 and 10 codes for these
disorders. Records for these patients, including demographics, medication usage, encounters and
diagnosis of comorbid diseases, were extracted from the EMR systems as an IRB (Institutional Review
Board)-approved HIPAA (Health Insurance Portability and Accountability Act) Limited Data Set.
These data included the dates for each transaction, using the University of Pittsburgh’s research data
warehouse. After data extraction, a sub-population that was diagnosed with both PTSD and bipolar
disorder was created.
SREs for this sub-population were identified from the EMRs. The diagnosis codes included ICD9
and ICD10 for suicidal ideation, attempt, and death based on literature reports [3,41]. The diagnosis
table was searched using the keywords ‘suicide’, ‘suicidal’ and ‘intentional self-harm’. Events of
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undetermined intent (Y10–Y34) were not considered. The lack of well-defined codes like X60–X70 in
the list might indicate a bias of coding preference in the UPMC EMR system.
The dates of first PTSD and bipolar disorder diagnoses of patients were extracted, with the later
date assigned to each patient as Both Diagnosed Time (BDT). SRE predictions were made at this time
point. Patients’ ages when they were diagnosed with both disorders were determined. Patients were
excluded that had SREs before BDT since the SREs may have not be casually linked to the diagnosis
of both PTSD and bipolar disorder. The time interval between BDT and an SRE was calculated for
high-risk patients. SREs within one year after BDT were marked as 1 (event identified). Patients with
follow-up times beyond one year that did not have an SRE or had it more than a year after BDT,
were marked as 0 (event not identified). Comorbid medical disorders were also documented and
categorized into 12 disease categories that used only ICD9 codes [17]. These ICD9 codes were mapped
to ICD10 codes using the service provided at http://www.icd10codesearch.com/. Patients having
dipolar disorder and PSTD diagnosis codes within a year prior to BDT were considered as having
these comorbid diseases.
Three major classes of medications taken into consideration as predictors were mood stabilizers,
antipsychotics, and antidepressives, and were extracted from DrugBank [42] (https://www.drugbank.ca/).
Patients were marked as taking these medications if they had been prescribed within one year prior
to their BDT to find predictor information for SREs at the point of BDT. Included in this study were
75 extracted medications from the three classes that were matched with medications recorded in
the EMR system. Medications included in this study are: Almotriptan, Amitriptyline, Amoxapine,
Amphetamine, Aripiprazole, Asenapine, Brexpiprazole, Bupropion, Buspirone, Carbamazepine,
Cariprazine, Chlorpheniramine, Chlorpromazine, Citalopram, Clomipramine, Clozapine, Desipramine,
Desvenlafaxine, Dexmethylphenidate, Dextromethorphan, Dihydroergotamine, Doxepin, Duloxetine,
Eletriptan, Escitalopram, Fentanyl, Flibanserin, Fluoxetine, Fluphenazine, Fluvoxamine, Frovatriptan,
Haloperidol, Iloperidone, Imipramine, Lamotrigine, Levomilnacipran, Lithium, Loxapine, Lurasidone,
Maprotiline, Meperidine, Methadone, Milnacipran, Mirtazapine, Naratriptan, Nefazodone, Nortriptyline,
Olanzapine, Paliperidone, Paroxetine, Perphenazine, Phenelzine, Pimozide, Promethazine, Protriptyline,
Quetiapine, Rasagiline, Risperidone, Rizatriptan, Ropinirole, Rotigotine, Selegiline, Sertraline, Sumatriptan,
Tapentadol, Thiothixene, Tramadol, Tranylcypromine, Trazodone, Trifluoperazine, Venlafaxine,
Vilazodone, Vortioxetine, Ziprasidone, and Zolmitriptan.
2.2. Software and Model Setup
The analysis algorithm was written in the Python programming language in a Jupyter notebook [43].
The ML-based models and calibration curves were developed by using scikit-learn 0.20.0 [44]. The key
Python libraries used in this analysis were SciPy [45], NumPy [46] and Pandas [47].
Several different ML-based classifiers were tested, including logistic regression [48],
random forest [49], decision tree [50], K-nearest neighbors [51], Naïve Bayes [52] and support
vector machine [53]. All models were set at a random state of 42 to ensure reproducibility while the
other hyper-parameters were left at default settings. The random state seeded the random number
generator used in the models. For the final random forest model, we set estimators to 100 and the
maximum number of features to the square root of the number of features.
ML-based models frequently encounter datasets that are heavily imbalanced—the number of
samples in the different classes are distributed unevenly—which affects their learning phases and
subsequent predictions. An over-sampling procedure based on the Synthetic Minority Oversampling
Technique (SMOTE) [54] was performed prior to conducting the analysis. The over-sampling procedure
creates new samples by connecting inliers and outliers from the original dataset [54]. The resampled
dataset was split into training and test datasets randomly in a 4:1 ratio. Only the training set was
oversampled with SMOTE so that the test set contained the original subjects in the dataset.
Many socioeconomic factors have been reported to play important roles in suicide prediction [55].
However, data from only the EMR were used as the predictors, variables, or features for modeling:
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(a) demographic data, including gender and age at BDT; (b) number of emergency department (ED)
visits and diagnoses within one year prior to the BDT; (c) medication usage within one year prior to the
BDT, including medication orders, dispenses, and fills. Medication usage data was coded by whether
patients had taken these medications within one year prior to their BDT.
Predictor or variable importance was calculated to assess key factors in SRE prediction.
In the random forest algorithm, predictor importance was quantified by evaluating the decrease
in “node impurity” at each split across all decision trees in the forest [56]. In the simplest case,
node impurity can be considered as the difference in measurement from controls at a node. The random
forest module uses these measures to estimate variances in nodes across trees. The nodes with
maximized response variances are those that have greater contributions to the differences in categories
of cases and have a greater impact on the model’s ability to predict outcomes.
Since patients with SREs are a minor class in our dataset, model performance was based on true
positive rate (TPR), positive predictive value (PPV), and negative predictive value (NPV) calculated as
follows (Equation (1)):
TPR = True Positives
(True Positives+False Negatives)
PPV = True Positives
(True Positives+False Positives)
NPV = True Negatives
(True Negatives+False Negatives)
(1)
Random forest results were interpreted using the python package TreeInterpreter 0.2.2 (https://github.
com/andosa/treeinterpreter), which allowed the (a) decomposition of each prediction into feature contribution
components in the training set mean and (b) identification of those features that affect the difference and
their contribution. In the model, all features will make contributions to the predication about an instance
whether positive or negative. If the value of a feature’s contribution was positive (SRE), the prediction value
was scored as 1. If the feature’s contribution was negative (no SRE), the prediction value was scored as 0.
3. Results
3.1. Model Construction and Performance
A total of 6042 patients with PTSD and bipolar disorder were identified from the EMR system
by ICD9 and ICD10 codes (Appendix A). Of this population, 4138 of them had no records of SRE
before BDT. Among these 4138 patients, 205 were identified as having SREs within one year after BDT,
while 3933 of them did not have SREs in the same time period. Patients with follow up time less than
one year and no reported SRE (970) were excluded from this study. The filtered 2963 subjects were
oversampled into a balanced dataset by SMOTE as described above. After data resample and split,
the training dataset contained 4726 subjects with 2363 subjects marked as 1 and 2363 subjects marked
as 0. The inclusion process is described in Figure 1 and the baseline patient characteristics are shown in
Table 1. Significant differences among patients with and without SREs because of gender, age, and ED
visits may be contributing variables in this study.
ML-based models were trained and evaluated with the data generated by the resample procedures.
Performances of all the models are shown as the means from a 5-fold stratified cross-validation process
(Table 2). TPR and PPV were prioritized since the model should be able to identify the high-risk
population within the precision constraints relevant to the data. Random forest was superior at
retrieving positive cases with less false positives with an exceptional high PPV (Table 2). Random forest
achieved an accuracy of 92.4%, an area under curve (AUC) of 95.6%, an F1 score of 0.879, and an area
under receiver operating characteristic (ROC) curve of 0.820. The random forest model was chosen as
the predictive model in the following analysis.
Brain Sci. 2020, 10, 784 5 of 27
Figure 1. Inclusion process of patients with PTSD and bipolar disorder.
Table 1. Baseline Patient Characteristics.
Characteristic Suicide(Percentage)
Not Suicide
(Percentage) p Value *
N = 205 N = 2963
Gender
Male 66 (32.2) 688 (23.2)
0.005Female 139 (67.8) 2275 (76.8)
Lithium Use
Yes 16 (7.8) 221 (7.5)
0.964Not 189 (92.2) 2742 (92.5)
ED Visits
10 ≤ X 15 (7.3) 93 (3.1) 0.003
5 ≤ X < 10 28 (13.7) 260 (8.8) 0.026
4 9 (4.4) 133 (4.5) 0.999
3 19 (9.3) 213 (7.2) 0.334
2 20 (9.8) 357 (12.0) 0.385
1 43 (21.0) 596 (20.1) 0.836
0 71 (34.6) 1311 (44.2) 0.009
Age
Mean (SD) 35.06 (12.92) 38.45 (13.29) <0.001
* p Values were generated with chi-square test.
3.2. Model Decomposition and Feature Importance Analysis
A decomposition analysis on the decision trees generated by the random forest algorithm was
conducted to better understand the contributions of each factor on SRE predictions. All features in
the model were examined individually to determine if the feature provided positive contributions.
Such an approach allowed a minimization of the data volume needed to make an accurate prediction
and to reduce computation expenses.
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TP 182 200.6 146 114.2 111.8 171
FP 888 2732.6 103.8 1238.8 1074.6 17
TN 2075 230.4 2859.2 1724.2 1888.4 2946
FN 23 4.4 59 90.8 93.2 34
TPR 0.888 0.979 0.712 0.557 0.545 0.834
PPV 0.17 0.068 0.585 0.084 0.094 0.91
NPV 0.989 0.981 0.98 0.95 0.953 0.989
TP: True positive, TN: True negative, FP: False positive, FN: False negative, TPR: True positive rate or Sensitivity,
PPV: Positive predictive value, NPV: Negative predictive value. * Values in the table are means from 5-fold stratified
cross validation.
Ninety-two features were used in the model including disease categories 1–12, the seventy-five
medications mentioned above, age, gender and ED visits. Among them, only age and ED visits were
continuous variables, and all other features were categorical. In order to find the features that are
necessary for the model and to minimize the data requirement, feature importance was calculated
using the method implemented in the package. Feature importance was calculated as the decrease in
node impurity weighted by the probability of reaching that node. The node probability was calculated
by the number of samples that reach the node, divided by the total number of samples. The higher the
value the more important the feature [57]
Multiple random forest tests, which included the top most important features, were performed
to retrain the model and test its performance. The performance of model improved as the number
of features with high importance increased (Figure 2). The performance curves reached a plateau at
approximately 30 features, then maintained a performance similar to the original model we trained
using all 90 features. As a result, the 30 most important features (Table 3) were used to train a simplified
random forest model.
Figure 2. Trends of model performances using different number of features. As shown in the figure,
the performance of model improved as we included more features in the model and it reached a plateau
at around 30 features. Therefore, we were able to achieve the similar model performance with much
less features.
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Table 3. Feature importance in random forest model.
Feature Feature Importance
Age at both diagnosed 0.141
Disease category 5 in last year 0.081
Disease category 3 in last year 0.07
Disease category 1 in last year 0.061
Trazodone 0.055
Fentanyl 0.047
Disease category 11 in last year 0.039
Emergency department visits in last year 0.038
Lamotrigine 0.036
Sertraline 0.031
Disease category 6 in last year 0.031


























Disease category 10 in last year 0.004
Paroxetine 0.004
Methadone 0.004





















































A simplified random forest model was built using the top 30 features. The ROC and the
Precision-Recall graphs of the new model were plotted (Figure 3). The random forest model outperforms
the no skill (random) model in both graphs (Figure 3). The simplified model yielded an accuracy of
98.3%, an AUC of 95.9% (similar to the original model performance), an F1 score of 0.868, and an ROC
of 0.811. The performance parameters for the retrained model achieved a high TPR and PPV with the
30 selected features, again similar to the original model performance (Table 2; Table 4). These results
indicate that the random forest model is sensitive to patients who had SREs and can predict SREs
correctly. Every feature that impacted the final prediction using random forest was processed through
the decomposition algorithms from treeinterpreter.
The random forest model was used to predict how each feature could impact the possibility of
having a SRE within one year after being BDT on all 3168 patients in the dataset. Of the 3168 patients,
the model correctly predicted SREs from 3120 of them. Contribution values (negative and positive) of
the features to correctly predicted presence of SREs within 1 year were calculated.
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Figure 3. ROC curve and Precision-Recall Curve for modified model. These two curves are the most
common measures to demonstrate the performance of a prediction model. Our model showed a F1
score of 0.877 and the area under ROC is 0.809 indicating a good precision and recall performance.
This means our model is very accurate and has a high sensitivity and specificity.
Table 4. Performance of model retrained on selected features.
TP FP TN FN TPR PPV NPV
Retrained model 171 14 2949 34 0.834 0.924 0.988
TP: True positive, TN: True negative, FP: False positive, FN: False negative, TPR: True positive rate or Sensitivity,
PPV: Positive predictive value, NPV: Negative predictive value.
The distributions for two continuous datasets, age and ED visits were investigated (Figure 4).
The age and ED distributions between positive and negative scores were significantly different (p < 0.001)
(Figure 4). Younger ages and more ED visits are associated with a higher risk of having SREs.
Figure 4. Distribution of age and ED visits in correctly predicted cases. Age distributions and ED
visits are significantly different in two groups. Younger patients and patients with more ED visits are
associated with higher-risk of SREs.
The distribution of the 28 categorical features provided an insight into how the individual features
impacted the SREs of individual cases (Figure 5). Generally speaking, value 1 tended to make a positive
contribution compared to 0 across all features. Specifically, features such as Fentanyl, Aripiprazole,
Disease category 11, Disease category 2 and Disease Category 6 showed obvious associations between
contributing groups and feature values. The value distributions of features are different in positive
and negative contributing groups (Figure 4) and these shifts can provide information about the impact
a feature may have on SREs. The difference in value distributions of features were examined using a
chi-square test (Table 5) and as a percentage in positive and negative contributing groups. If a feature
has no or little association with the final prediction, the percentages of patients taken medication
or have the comorbid disease in positive and negative contributing groups should be similar to the
percentage of 1 in the whole population. If the percentage of patients taken medication or have the
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comorbid disease in positive or negative contributing group significantly differs from that of the whole
population and each other, it suggests a possible mechanistic association between this feature and the
potential risk for an SRE. For example, 11.6% of the participants have taken Sertraline. They account
for 0% of the positive contributing groups and 45.9% of negative contributing groups. It can be
concluded that taking Sertraline is predictive for no SREs within one year. High-importance features
with an obvious separation pattern among the population groups have also been identified (Table 3).
This indicates that the values of these features can greatly impact the final SRE predictions and may
inform future mechanism studies.
Figure 5. Distribution of feature values with positive and negative contributions. Most 0 values are
associated with a higher risk of suicide and 1 are considered having lower risks. 0 means that the patients did
not have the disease or did not take the medication and 1 means they did. Some features showed obvious
separation in contributions by values which means the values of these features are strongly associated with
the final prediction( CatN_1Year: Disease Category N in last year (N = 1, 2, 3, 4, 5, 6 and 11)).

















in last year 2065.444 <0.001 0.064 0.919 0.017 <0.001 SREs
Disease category
11 in last year 2239.822 <0.001 0.098 0.996 0.027 <0.001 SREs
Disease category 6
in last year 1750.073 <0.001 0.066 0.846 0.021 <0.001 SREs
Disease category 1
in last year 2193.804 <0.001 0.232 1 0.068 <0.001 SREs
Trazodone 1248.659 <0.001 0.17 0.996 0.101 <0.001 SREs
Sertraline 1205.388 <0.001 0.116 0 0.459 <0.001 No SREs
GENDER 681.776 <0.001 0.237 0.062 0.463 <0.001 No SREs
Haloperidol 489.011 <0.001 0.046 0.32 0.021 <0.001 SREs
Fentanyl 486.882 <0.001 0.188 0.002 0.317 <0.001 No SREs
Aripiprazole 428.686 <0.001 0.089 0.003 0.219 <0.001 No SREs
Lamotrigine 424.696 <0.001 0.146 0.001 0.264 <0.001 No SREs
Disease category 4
in last year 422.183 <0.001 0.034 0.261 0.014 <0.001 SREs
Ziprasidone 348.145 <0.001 0.037 0.202 0.013 <0.001 SREs
Risperidone 326.949 <0.001 0.063 0.378 0.043 <0.001 SREs
Mirtazapine 166.917 <0.001 0.063 0.186 0.037 <0.001 SREs

















Quetiapine 127.63 <0.001 0.135 0.32 0.109 <0.001 SREs
Venlafaxine 119.404 <0.001 0.082 0.214 0.06 <0.001 SREs
Buspirone 111.025 <0.001 0.079 0.024 0.126 <0.001 No SREs
Disease category 5
in last year 108.425 <0.001 0.46 0.989 0.443 <0.001 SREs
Duloxetine 104.213 <0.001 0.069 0.175 0.048 <0.001 SREs
Tramadol 76.116 <0.001 0.131 0.038 0.162 <0.001 No SREs
Citalopram 63.62 <0.001 0.124 0.233 0.103 <0.001 SREs
Bupropion 18.005 <0.001 0.109 0.066 0.122 <0.001 No SREs
Fluoxetine 14.305 <0.001 0.092 0.065 0.107 <0.001 No SREs
Disease category 3
in last year 14.02 <0.001 0.749 0.907 0.744 <0.001 SREs
Promethazine 7.757 0.005 0.052 0.038 0.061 0.006 No SREs
Lithium 5.165 0.023 0.076 0.058 0.083 0.024 No SREs
Olanzapine 1.026 0.311 0.054 0.048 0.057 0.311 N/A
All features except Olanzapine showed a significant difference between their distributions in
positive and negative contributing groups. This is the result we are expecting because all the features
in Figure 5 have been selected through the drop column feature importance test and were identified
as important for the model to make the prediction. If the value of a certain feature does not provide
significant differences in the percentages among the groups, it is likely that it has no benefit in for
predicting SREs and will be dropped in the previous step. The results shown in Table 5 provided
additional support to our feature selection process above.
4. Discussion and Conclusions
Prior studies have found that the ML-based methods perform better at identifying suicide risks in
large populations of patients than traditional methods. The accuracies of these studies are reported to
be between 0.76–0.79 with AUCs generally between 0.80–0.90 [15,17,58]. The objective of this study
was to find an ML-based method that identifies patients at high-risk for SREs—patients diagnosed
with both PTSD and bipolar disorder. This study demonstrated an accuracy of 0.92 and an AUC of
0.956 using the random forest method. The random forest model can accurately predict those patients
at higher risk of SREs as evaluated with TPR and PPV tests. Sub-populations suffering from certain
disorders and taking certain medications can be distinguished from a larger population as having a
higher risk for SREs.
Different features have different contributions to the prediction of SREs. These features are mental
disorders and drug administration history within one year. As discussed by Sanderson et al. [17],
mental health diagnoses were separated into twelve disease categories based on their ICD9 codes
(Appendix B). Patients suffering from comorbid diseases at BDT are more likely to have SRE within
a year. These comorbid diseases include: Category 11, autistic disorder-current and disturbance of
conduct; Category 3, mood disorders and adjustment disorders; Category 4, other psychotic disorders;
and Category 5, acute stress reactions. Several studies have reported results that diseases in Category
11 are more likely to trigger SRE [59–62]. Numerous studies have provided evidence that mental
disorders have the potential to increase the risk of SREs [63,64]. This evidence is supported by the
results of the random forest model presented here.
For the unselected features, it does not mean that these features may not be useful predictors of
SREs. The aim of the feature selection process to use a sufficient but minimal number of features for
the model to achieve optimal prediction results. It was found that optimal results were found using
30 features and that the addition of additional features did not affect the results. The distribution
of all categorical features is attached (Appendix C). The impurity-based feature importance can be
misleading for high cardinality features and continuous variables (age and ED visits) [65]. For this
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reason, the distribution of these two variables were examined first to ensure that their association with
SREs are not the result of biased algorithms.
With medication usage as the feature, some of them showed a much higher proportion in the
negative contributing group compared to either the whole population or the positive contributing
groups (Fentanyl, Levomilnacipran, Sertraline, Aripiprazole, Tramadol, Lamotrigine, Sertraline,
and Fluoxetine). These medications are considered to reduce the risk of SREs within one year in our
model. Other investigators have shown similar beneficial effects in clinical trials [66,67]. However,
some studies have found that Tramadol, Aripiprazole, and Fentanyl have not been associated with
risk reduction in SREs. Thus, our results may provide support for further investigations. The model
identified several medications that increased the risk of SREs. Such medications have also been
reported to increase the risk of SREs in other studies [68]. Caution must be taken in interpreting the
effect of medications on the prediction of SREs in that the model’s results do not account for drugs that
may be indicators of comorbidities, e.g., sleep problems that may alter the risk of SREs.
The results of our study made it possible for clinicians to identify patients who have a higher risk
of SREs and have additional insight of how to reduce this risk by identified risk factors. Clinicians will
be able to adjust the medications to replace some drugs which increase the risk of SREs with drugs
with the same class with less risk or focus on relieving the symptoms which may contribute most to
the suicide risk.
The ML-based random forest model provides a basis for clinicians to build similar models for
different populations facing different disease risks. Our model is built with open source Python
packages and trained based on EMR data. This means other researchers can test our model in other
clinical samples. Also, our study can provide guidance for clinical institutions or other researchers to
build their own models for other kinds of populations.
Unavoidably, there are limitations to this study. (a) the data was collected from hospitals affiliated
with UPMC. External data for validation was not used and, if included, may have led to overfitting;
(b) most clinicians prefer to treat diseases and disorders with particular combinations of drugs different
from those used by other clinicians. This may cause bias in the results among institutions if such
preferences are widely used in the hospital, despite alternative drug choices; (c) the high prediction
performance of the model may due to the unique characteristics of the BDT patient subpopulation.
The model may need further adjustment and optimization to apply it to other high-suicide risk
populations or other disease states; (d) mis-diagnoses and biased prescriptions are two problems may
cause errors in the predictions of SREs. PTSD and bipolar disorder may be mis-diagnosed as other
diseases in their early stages, which may cause bias in our model, especially with younger patients.
However, the ability to identify mis-diagnoses and biased prescriptions from the EMR is beyond
the capability of our model; (e) though some medications, like lithium, may not be indicated for
SREs, clinicians prescribe them for bipolar disorders to a greater extent due to its known anti-suicidal
properties. This may be the situation in many clinical practices.
The ML-based random forest model makes it possible for clinicians to identify subpopulations
of patients who have a higher risk of SREs and to have additional insights to reducing this risk by
identifying individual risk factors. Medications that increase the risk of SREs can be substituted with
drugs having a lower risk or that focus on relieving symptoms that may contribute most to SREs.
Using EMR information, a ML-based random forest model was constructed that predicts, with an
accuracy of around 90%, if a patient will have an SRE within the following year of the diagnosis of
both bipolar disorder and PSTD. The model extracts features that make contributions to the risk of
SREs, which can be further utilized in mechanism studies. The model has great potential as a clinical
tool that can aid clinicians in identifying high-risk individuals and to better guide patient clinical care.
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Appendix A. ICD9 and ICD10 Codes for PTSD, Bipolar Disorder and Suicide Events
PTSD: 309.81, F43.10, F43.11, F43.12
Bipolar disorder: 296.8, 296.89, 296.7, F31.81, 296.5, F31.32, F31.89, 296.53, 296.54, F31.4, 296.6,
296.44, F31.75, 296, 296.52, F31.12, F31.30, F31.70, F31.2, F31.31, 296.4, F31.0, F31.62, F31.5, 296.64, 296.42,
F31.76, F31.13, 296.62, F31.11, F31.60, 296.41, F31.61, 296.63, F31.77, F31.10, F31.71, 296.51, 296.46, 296.43,
296.55, F31.63, F31.73, F31.78, 296.45, 296.66, 296.61, F31.74, F31.64, 296.02, F31.72, 296.56, 296.01, 296.03,
296.65, 296.06, 296.6, 296.04, 296.8, 296.05
Table A1. Suicide-Related Events.
ICD Code Diagnosis Name #Patients in 205 Patients
R45.851 Suicidal ideations 83
V62.84 Suicidal ideation 78
E950.4 Suicide and self-inflicted poisoning by otherspecified drugs and medicinal substances 9
E950.3 Suicide and self-inflicted poisoning by tranquilizersand other psychotropic agents 7
E956 Suicide and self-inflicted injury by cutting andpiercing instrument 6
E958.8 Suicide and self-inflicted injury by otherspecified means 5
T43.222A Poisoning by selective serotonin reuptake inhibitors,intentional self-harm, initial encounter 2
X78.9XXA Intentional self-harm by unspecified sharp object,initial encounter 2
E950.0 Suicide and self-inflicted poisoning by analgesics,antipyretics, and antirheumatics 1
E950.2 Suicide and self-inflicted poisoning by othersedatives and hypnotics 1
T14.91XA Suicide attempt, initial encounter 1
T39.1X2A Poisoning by 4-Aminophenol derivatives, intentionalself-harm, initial encounter 1
T40.1X2A Poisoning by heroin, intentional self-harm,initial encounter 1
T42.1X2A Poisoning by iminostilbenes, intentional self-harm,initial encounter 1
T42.4X2A Poisoning by benzodiazepines, intentional self-harm,initial encounter 1
T42.4X2D Poisoning by benzodiazepines, intentional self-harm,subsequent encounter 0
T42.6X2A
Poisoning by other antiepileptic and




Poisoning by selective serotonin and norepinephrine
reuptake inhibitors, intentional self-harm,
initial encounter
1
T46.5X2A Poisoning by other antihypertensive drugs,intentional self-harm, initial encounter 1
T50.902D
Poisoning by unspecified drugs, medicaments and
biological substances, intentional self-harm,
subsequent encounter
0
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ICD Code Diagnosis Name #Patients in 205 Patients
T65.92XD Toxic effect of unspecified substance, intentionalself-harm, subsequent encounter 0
T71.162A Asphyxiation due to hanging, intentional self-harm,initial encounter 1
X78.8XXA Intentional self-harm by other sharp object,initial encounter 1
X78.9XXD Intentional self-harm by unspecified sharp object,subsequent encounter 0
X83.8XXA Intentional self-harm by other specified means,initial encounter 1
E950.1 Suicide and self-inflicted poisoning by barbiturates 0
E950.5 Suicide and self-inflicted poisoning by unspecifieddrug or medicinal substance 0
E950.6
Suicide and self-inflicted poisoning by agricultural
and horticultural chemical and pharmaceutical
preparations other than plant foods and fertilizers
0
E950.7 Suicide and self-inflicted poisoning by corrosive andcaustic substances 0
E950.9 Suicide and self-inflicted poisoning by other andunspecified solid and liquid substances 0
E951.0 Suicide and self-inflicted poisoning by gasdistributed by pipeline 0
E951.8 Suicide and self-inflicted poisoningby other utility gas 0
E952.0 Suicide and self-inflicted poisoning by motor vehicleexhaust gas 0
E952.1 Suicide and self-inflicted poisoning by other carbonmonoxide 0
E952.8 Suicide and self-inflicted poisoning by otherspecified gases and vapors 0
E953.0 Suicide and self-inflicted injury by hanging 0
E953.1 Suicide and self-inflicted injury by suffocation byplastic bag 0
E953.8 Suicide and self-inflicted injury by other specifiedmeans 0
E953.9 Suicide and self-inflicted injury by unspecified means 0
E954 Suicide and self-inflicted injury by submersion[drowning] 0
E955.0 Suicide and self-inflicted injury by handgun 0
E955.1 Suicide and self-inflicted injury by shotgun 0
E955.2 Suicide and self-inflicted injury by hunting rifle 0
E955.4 Suicide and self-inflicted injury by other andunspecified firearm 0
E955.9 Suicide and self-inflicted injury by firearms andexplosives, unspecified 0
E957.0 Suicide and self-inflicted injuries by jumping fromresidential premises 0
E957.1 Suicide and self-inflicted injuries by jumping fromother man-made structures 0
E957.9 Suicide and self-inflicted injuries by jumping fromunspecified site 0
E958.0 Suicide and self-inflicted injury by jumping or lyingbefore moving object 0
E958.1 Suicide and self-inflicted injury by burns, fire 0
E958.2 Suicide and self-inflicted injury by scald 0
E958.3 Suicide and self-inflicted injury by extremes of cold 0
E958.5 Suicide and self-inflicted injury by crashing ofmotor vehicle 0
E958.6 Suicide and self-inflicted injury by crashing of aircraft 0
E958.7 Suicide and self-inflicted injury by caustic substances,except poisoning 0
E958.9 Suicide and self-inflicted injury by unspecified means 0
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ICD Code Diagnosis Name #Patients in 205 Patients
T14.91 Suicide attempt 0
T14.91XD Suicide attempt, subsequent encounter 0
T14.91XS Suicide attempt, sequela 0
T36.0X2A Poisoning by penicillins, intentional self-harm,initial encounter 0
T36.0X2D Poisoning by penicillins, intentional self-harm,subsequent encounter 0
T36.1X2A Poisoning by cephalosporins and other beta-lactamantibiotics, intentional self-harm, initial encounter 0
T36.3X2A Poisoning by macrolides, intentional self-harm,initial encounter 0
T36.4X2A Poisoning by tetracyclines, intentional self-harm,initial encounter 0
T36.8X2A Poisoning by other systemic antibiotics, intentionalself-harm, initial encounter 0
T37.5X2A Poisoning by antiviral drugs, intentional self-harm,initial encounter 0
T37.8X2A
Poisoning by other specified systemic anti-infectives
and antiparasitics, intentional self-harm, initial
encounter
0
T38.1X2A Poisoning by thyroid hormones and substitutes,intentional self-harm, initial encounter 0
T38.2X2A Poisoning by antithyroid drugs, intentionalself-harm, initial encounter 0
T38.3X2A
Poisoning by insulin and oral hypoglycemic




Poisoning by insulin and oral hypoglycemic
[antidiabetic] drugs, intentional self-harm,
subsequent encounter
0
T38.5X2A Poisoning by other estrogens and progestogens,intentional self-harm, initial encounter 0
T38.892A Poisoning by other hormones and syntheticsubstitutes, intentional self-harm, initial encounter 0
T39.012A Poisoning by aspirin, intentional self-harm, initialencounter 0
T39.012D Poisoning by aspirin, intentional self-harm,subsequent encounter 0
T39.092A Poisoning by salicylates, intentional self-harm, initialencounter 0
T39.1X2D Poisoning by 4-Aminophenol derivatives, intentionalself-harm, subsequent encounter 0
T39.312A Poisoning by propionic acid derivatives, intentionalself-harm, initial encounter 0
T39.312D Poisoning by propionic acid derivatives, intentionalself-harm, subsequent encounter 0
T39.392A
Poisoning by other nonsteroidal anti-inflammatory
drugs [NSAID], intentional self-harm, initial
encounter
0
T39.4X2A Poisoning by antirheumatics, not elsewhereclassified, intentional self-harm, initial encounter 0
T39.8X2A
Poisoning by other nonopioid analgesics and




Poisoning by unspecified nonopioid analgesic,
antipyretic and antirheumatic, intentional self-harm,
initial encounter
0
T40.1X2D Poisoning by heroin, intentional self-harm,subsequent encounter 0
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T40.2X2A Poisoning by other opioids, intentional self-harm,initial encounter 0
T40.2X2D Poisoning by other opioids, intentional self-harm,subsequent encounter 0
T40.3X2A Poisoning by methadone, intentional self-harm,initial encounter 0
T40.4X2A Poisoning by other synthetic narcotics, intentionalself-harm, initial encounter 0
T40.5X2A Poisoning by cocaine, intentional self-harm, initialencounter 0
T40.5X2D Poisoning by cocaine, intentional self-harm,subsequent encounter 0
T40.602A Poisoning by unspecified narcotics, intentionalself-harm, initial encounter 0
T40.602D Poisoning by unspecified narcotics, intentionalself-harm, subsequent encounter 0
T40.7X2A Poisoning by cannabis (derivatives), intentionalself-harm, initial encounter 0
T40.8X2A Poisoning by lysergide [LSD], intentional self-harm,initial encounter 0
T40.8X2D Poisoning by lysergide [LSD], intentional self-harm,subsequent encounter 0
T40.992A Poisoning by other psychodysleptics [hallucinogens],intentional self-harm, initial encounter 0
T41.292A Poisoning by other general anesthetics, intentionalself-harm, initial encounter 0
T41.3X2A Poisoning by local anesthetics, intentional self-harm,initial encounter 0
T42.0X2A Poisoning by hydantoin derivatives, intentionalself-harm, initial encounter 0
T42.3X2A Poisoning by barbiturates, intentional self-harm,initial encounter 0
T42.4X2S Poisoning by benzodiazepines, intentional self-harm,sequela 0
T42.5X2A Poisoning by mixed antiepileptics, intentionalself-harm, initial encounter 0
T42.6X2 Poisoning by other antiepileptic andsedative-hypnotic drugs, intentional self-harm 0
T42.6X2D
Poisoning by other antiepileptic and




Poisoning by unspecified antiepileptic and




Poisoning by antiparkinsonism drugs and other
central muscle-tone depressants, intentional
self-harm, initial encounter
0
T43.012A Poisoning by tricyclic antidepressants, intentionalself-harm, initial encounter 0
T43.012D Poisoning by tricyclic antidepressants, intentionalself-harm, subsequent encounter 0
T43.022A Poisoning by tetracyclic antidepressants, intentionalself-harm, initial encounter 0
T43.022D Poisoning by tetracyclic antidepressants, intentionalself-harm, subsequent encounter 0
T43.1X2A
Poisoning by monoamine-oxidase-inhibitor
antidepressants, intentional self-harm, initial
encounter
0
T43.202A Poisoning by unspecified antidepressants, intentionalself-harm, initial encounter 0
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T43.212D
Poisoning by selective serotonin and norepinephrine
reuptake inhibitors, intentional self-harm,
subsequent encounter
0
T43.222D Poisoning by selective serotonin reuptake inhibitors,intentional self-harm, subsequent encounter 0
T43.292A Poisoning by other antidepressants, intentionalself-harm, initial encounter 0
T43.292D Poisoning by other antidepressants, intentionalself-harm, subsequent encounter 0
T43.3X2A Poisoning by phenothiazine antipsychotics andneuroleptics, intentional self-harm, initial encounter 0
T43.3X2D




T43.4X2A Poisoning by butyrophenone and thiothixeneneuroleptics, intentional self-harm, initial encounter 0
T43.502A Poisoning by unspecified antipsychotics andneuroleptics, intentional self-harm, initial encounter 0
T43.592A Poisoning by other antipsychotics and neuroleptics,intentional self-harm, initial encounter 0
T43.592D Poisoning by other antipsychotics and neuroleptics,intentional self-harm, subsequent encounter 0
T43.612A Poisoning by caffeine, intentional self-harm,initial encounter 0
T43.622A Poisoning by amphetamines, intentional self-harm,initial encounter 0
T43.622D Poisoning by amphetamines, intentional self-harm,subsequent encounter 0
T43.632A Poisoning by methylphenidate, intentional self-harm,initial encounter 0
T43.692A Poisoning by other psychostimulants, intentionalself-harm, initial encounter 0
T43.8X2A Poisoning by other psychotropic drugs, intentionalself-harm, initial encounter 0
T43.92XA Poisoning by unspecified psychotropic drug,intentional self-harm, initial encounter 0
T44.1X2A Poisoning by other parasympathomimetics[cholinergics], intentional self-harm, initial encounter 0
T44.3X2A
Poisoning by other parasympatholytics
[anticholinergics and antimuscarinics] and
spasmolytics, intentional self-harm, initial encounter
0
T44.4X2A Poisoning by predominantly alpha-adrenoreceptoragonists, intentional self-harm, initial encounter 0
T44.6X2A Poisoning by alpha-adrenoreceptor antagonists,intentional self-harm, initial encounter 0
T44.7X2A Poisoning by beta-adrenoreceptor antagonists,intentional self-harm, initial encounter 0
T44.7X2D Poisoning by beta-adrenoreceptor antagonists,intentional self-harm, subsequent encounter 0
T44.992A
Poisoning by other drug primarily affecting the
autonomic nervous system, intentional self-harm,
initial encounter
0
T45.0X2A Poisoning by antiallergic and antiemetic drugs,intentional self-harm, initial encounter 0
T45.0X2D Poisoning by antiallergic and antiemetic drugs,intentional self-harm, subsequent encounter 0
T45.2X2A Poisoning by vitamins, intentional self-harm,initial encounter 0
T45.2X2D Poisoning by vitamins, intentional self-harm,subsequent encounter 0
T45.4X2A Poisoning by iron and its compounds, intentionalself-harm, initial encounter 0
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T45.512A Poisoning by anticoagulants, intentional self-harm,initial encounter 0
T46.0X2A
Poisoning by cardiac-stimulant glycosides and drugs
of similar action, intentional self-harm,
initial encounter
0
T46.1X2A Poisoning by calcium-channel blockers, intentionalself-harm, initial encounter 0
T46.2X2A Poisoning by other antidysrhythmic drugs,intentional self-harm, initial encounter 0
T46.3X2A Poisoning by coronary vasodilators, intentionalself-harm, initial encounter 0






T46.5X2D Poisoning by other antihypertensive drugs,intentional self-harm, subsequent encounter 0
T46.6X2A
Poisoning by antihyperlipidemic and
antiarteriosclerotic drugs, intentional self-harm,
initial encounter
0
T46.7X2A Poisoning by peripheral vasodilators, intentionalself-harm, initial encounter 0
T46.8X2A Poisoning by antivaricose drugs, including sclerosingagents, intentional self-harm, initial encounter 0
T47.0X2A Poisoning by histamine H2-receptor blockers,intentional self-harm, initial encounter 0
T47.1X2A Poisoning by other antacids and anti-gastric-secretiondrugs, intentional self-harm, initial encounter 0
T47.4X2A Poisoning by other laxatives, intentional self-harm,initial encounter 0
T47.6X2A Poisoning by antidiarrheal drugs, intentionalself-harm, initial encounter 0
T48.1X2A
Poisoning by skeletal muscle relaxants
[neuromuscular blocking agents], intentional
self-harm, initial encounter
0
T48.202A Poisoning by unspecified drugs acting on muscles,intentional self-harm, initial encounter 0
T48.3X2A Poisoning by antitussives, intentional self-harm,initial encounter 0
T48.3X2D Poisoning by antitussives, intentional self-harm,subsequent encounter 0
T48.4X2A Poisoning by expectorants, intentional self-harm,initial encounter 0
T48.5X2A Poisoning by other anti-common-cold drugs,intentional self-harm, initial encounter 0
T48.6X2A Poisoning by antiasthmatics, intentional self-harm,initial encounter 0
T49.0X2A
Poisoning by local antifungal, anti-infective and
anti-inflammatory drugs, intentional self-harm,
initial encounter
0
T49.6X2A Poisoning by otorhinolaryngological drugs andpreparations, intentional self-harm, initial encounter 0
T49.6X2D





Poisoning by carbonic-anhydrase inhibitors,




Poisoning by carbonic-anhydrase inhibitors,
benzothiadiazides and other diuretics, intentional
self-harm, subsequent encounter
0
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T50.3X2A Poisoning by electrolytic, caloric and water-balanceagents, intentional self-harm, initial encounter 0
T50.5X2A Poisoning by appetite depressants, intentionalself-harm, initial encounter 0
T50.6X2A Poisoning by antidotes and chelating agents,intentional self-harm, initial encounter 0
T50.7X2A Poisoning by analeptics and opioid receptorantagonists, intentional self-harm, initial encounter 0
T50.8X2A Poisoning by diagnostic agents, intentional self-harm,initial encounter 0
T50.902A
Poisoning by unspecified drugs, medicaments and
biological substances, intentional self-harm,
initial encounter
0
T50.902S Poisoning by unspecified drugs, medicaments andbiological substances, intentional self-harm, sequela 0
T50.992A
Poisoning by other drugs, medicaments and




Poisoning by other drugs, medicaments and
biological substances, intentional self-harm,
subsequent encounter
0
T51.0X2A Toxic effect of ethanol, intentional self-harm,initial encounter 0
T51.0X2D Toxic effect of ethanol, intentional self-harm,subsequent encounter 0
T51.1X2A Toxic effect of methanol, intentional self-harm,initial encounter 0
T51.2X2A Toxic effect of 2-Propanol, intentional self-harm,initial encounter 0
T51.2X2D Toxic effect of 2-Propanol, intentional self-harm,subsequent encounter 0
T51.2X2S Toxic effect of 2-Propanol,intentional self-harm, sequela 0
T51.8X2A Toxic effect of other alcohols, intentional self-harm,initial encounter 0
T51.92XA Toxic effect of unspecified alcohol, intentionalself-harm, initial encounter 0
T51.92XD Toxic effect of unspecified alcohol, intentionalself-harm, subsequent encounter 0
T52.0X2A Toxic effect of petroleum products, intentionalself-harm, initial encounter 0
T52.4X2A Toxic effect of ketones, intentional self-harm,initial encounter 0
T52.8X2A Toxic effect of other organic solvents, intentionalself-harm, initial encounter 0
T54.0X2A Toxic effect of phenol and phenol homologues,intentional self-harm, initial encounter 0
T54.1X2A Toxic effect of other corrosive organic compounds,intentional self-harm, initial encounter 0
T54.2X2A Toxic effect of corrosive acids and acid-likesubstances, intentional self-harm, initial encounter 0
T54.3X2A Toxic effect of corrosive alkalis and alkali-likesubstances, intentional self-harm, initial encounter 0
T54.3X2D




T54.3X2S Toxic effect of corrosive alkalis and alkali-likesubstances, intentional self-harm, sequela 0
T54.92XA Toxic effect of unspecified corrosive substance,intentional self-harm, initial encounter 0
T54.92XS Toxic effect of unspecified corrosive substance,intentional self-harm, sequela 0
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T55.0X2A Toxic effect of soaps, intentional self-harm,initial encounter 0
T55.1X2A Toxic effect of detergents, intentional self-harm,initial encounter 0
T56.892A Toxic effect of other metals, intentional self-harm,initial encounter 0
T56.892D Toxic effect of other metals, intentional self-harm,subsequent encounter 0
T58.02XA Toxic effect of carbon monoxide from motor vehicleexhaust, intentional self-harm, initial encounter 0
T58.92XA Toxic effect of carbon monoxide from unspecifiedsource, intentional self-harm, initial encounter 0
T59.892A Toxic effect of other specified gases, fumes andvapors, intentional self-harm, initial encounter 0
T62.0X2A Toxic effect of ingested mushrooms, intentionalself-harm, initial encounter 0
T65.222D Toxic effect of tobacco cigarettes, intentionalself-harm, subsequent encounter 0
T65.222S Toxic effect of tobacco cigarettes, intentionalself-harm, sequela 0
T65.892A Toxic effect of other specified substances, intentionalself-harm, initial encounter 0
T65.892D Toxic effect of other specified substances, intentionalself-harm, subsequent encounter 0
T65.92XA Toxic effect of unspecified substance, intentionalself-harm, initial encounter 0
T65.92XS Toxic effect of unspecified substance, intentionalself-harm, sequela 0
T71.162D Asphyxiation due to hanging, intentional self-harm,subsequent encounter 0
T71.192A
Asphyxiation due to mechanical threat to breathing
due to other causes, intentional self-harm, initial
encounter
0
X71.0XXS Intentional self-harm by drowning and submersionwhile in bathtub, sequela 0
X71.3XXA Intentional self-harm by drowning and submersionin natural water, initial encounter 0
X71.8XXA Other intentional self-harm by drowning andsubmersion, initial encounter 0
X71.9XXA Intentional self-harm by drowning and submersion,unspecified, initial encounter 0
X72.XXXA Intentional self-harm by handgun discharge, initialencounter 0
X72.XXXD Intentional self-harm by handgun discharge,subsequent encounter 0
X72.XXXS Intentional self-harm by handgun discharge, sequela 0
X73.0XXA Intentional self-harm by shotgun discharge, initialencounter 0
X74.01XA Intentional self-harm by airgun, initial encounter 0
X74.8XXS Intentional self-harm by other firearm discharge,sequela 0
X74.9XXA Intentional self-harm by unspecified firearmdischarge, initial encounter 0
X74.9XXD Intentional self-harm by unspecified firearmdischarge, subsequent encounter 0
X74.9XXS Intentional self-harm by unspecified firearmdischarge, sequela 0
X76.XXXA Intentional self-harm by smoke, fire and flames,initial encounter 0
X76.XXXD Intentional self-harm by smoke, fire and flames,subsequent encounter 0
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X77.8XXA Intentional self-harm by other hot objects,initial encounter 0
X78.0XXA Intentional self-harm by sharp glass, initial encounter 0
X78.0XXD Intentional self-harm by sharp glass,subsequent encounter 0
X78.1XXA Intentional self-harm by knife, initial encounter 0
X78.1XXD Intentional self-harm by knife, subsequent encounter 0
X78.8XXD Intentional self-harm by other sharp object,subsequent encounter 0
X78.9XXS Intentional self-harm by unspecifiedsharp object, sequela 0
X79.XXXA Intentional self-harm by blunt object,initial encounter 0
X79.XXXD Intentional self-harm by blunt object,subsequent encounter 0
X80.XXXA Intentional self-harm by jumping from a high place,initial encounter 0
X80.XXXD Intentional self-harm by jumping from a high place,subsequent encounter 0
X81.0XXA Intentional self-harm by jumping or lying in front ofmotor vehicle, initial encounter 0
X81.8XXA Intentional self-harm by jumping or lying in front ofother moving object, initial encounter 0
X82.8XXA Other intentional self-harm by crashing of motorvehicle, initial encounter 0
X83.2XXA Intentional self-harm by exposure to extremes of cold,initial encounter 0
X83.8XXD Intentional self-harm by other specified means,subsequent encounter 0
X83.8XXS Intentional self-harm by other specified means,sequela 0
Appendix B. Categories of Comorbid Diseases
Comorbid medical disorders were also documented and categorized into 12 disease categories
that used only ICD9 codes [42].
Category 1 (ICD9: 291* or 292* or 303* or 304* or (305* and not 305.1))
Category 2 (ICD9: 295* or 301.2)
Category 3 (ICD9: 296* or 298.0 or 300.4 or 301.1 or 309* or 311*)
Category 4 (ICD9: 297* or (298* and not 298.0))
Category 5 (ICD9: 308* or (300* and not 300.4))
Category 6 (ICD9: 301* not 301.1 and not 301.2)
Category 7 (ICD9: 302*)
Category 8 (ICD9: 306* or 316*)
Category 9 (ICD9: 307*)
Category 10 (ICD9: 290* or 293* or 294* or 310*)
Category 11 (ICD9: 299* or 312* or 313* or 314* or 315*)
Category 12 (ICD9: 317* or 318* or 319*)
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292 Drug-induced mentaldisorders 1 302
Sexual and gender
identity disorders 7





304 Drug dependence 1 316 Psychic factor w oth dis. 8
305 (not 305.1)
Nondependent abuse







295 Schizophrenicdisorders 2 290 Dementias 10












298 Depressive typepsychosis 3 310
Specific nonpsychotic
mental disorders due to
brain damage
10
300.4 Dysthymic disorder 3 299 Autistic disorder-current 11
301.1 Affective personalitydisorder 3 312
Disturbance of conduct
not elsewhere classified 11
309 Adjustment reaction 3 313
Disturbance of emotions
specific to childhood and
adolescence
11
311 Depressive disorderNEC 3 314
Hyperkinetic syndrome
of childhood 11
297 Delusional disorders 4 315 Specific delays indevelopment 11





4 317 Mild intellectualdisabilities 12
308 Acute reaction to stress 5 318 Other specifiedintellectual disabilities 12





5 319 Unspecified intellectualdisabilities 12
Appendix C. Distribution of All Categorical Features
Table A3. Distribution of all categorical features.
T P














Almotriptan 18.747 <0.001 0.013 0 1 <0.001 No SREs
Sertraline 1027.936 <0.001 0.117 0 0.41 <0.001 No SREs
Selegiline 250.75 <0.001 0.001 1 0 <0.001 SREs
Rotigotine 130.307 <0.001 0.009 0 1 <0.001 No SREs
Rizatriptan 136.995 <0.001 0.013 0.071 0.003 <0.001 SREs
Risperidone 32.548 <0.001 0.062 0.131 0.053 <0.001 SREs
Rasagiline 16.996 <0.001 0.014 0 1 <0.001 No SREs
Sumatriptan 355.971 <0.001 0.051 0.004 0.169 <0.001 No SREs
Quetiapine 34.748 <0.001 0.135 0.068 0.155 <0.001 No SREs
Promethazine 130.817 <0.001 0.053 0.008 0.1 <0.001 No SREs
Paroxetine 78.278 <0.001 0.032 0.008 0.065 <0.001 No SREs
Olanzapine 174.851 <0.001 0.055 0.184 0.032 <0.001 SREs
Disease Category
12 in last year 150.338 <0.001 0.011 0.098 0.004 <0.001 SREs
Mirtazapine 113.859 <0.001 0.063 0.013 0.106 <0.001 No SREs
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Milnacipran 1014.193 <0.001 0.007 0 1 <0.001 No SREs
Protriptyline 120.749 <0.001 0.002 0 1 <0.001 No SREs
Tapentadol 67.865 <0.001 0.016 0 1 <0.001 No SREs
Thiothixene 27.267 <0.001 0.001 0.029 0 <0.001 SREs
Tramadol 855.263 <0.001 0.131 0.002 0.373 <0.001 No SREs
Disease Category
11 in last year 1879.785 <0.001 0.098 0.957 0.036 <0.001 SREs
Disease Category
9 in last year 95.725 <0.001 0.043 0.008 0.079 <0.001 No SREs
Disease Category
8 in last year 44.042 <0.001 0.005 0.042 0.002 <0.001 SREs
Disease Category
7 in last year 259.428 <0.001 0.012 0 1 <0.001 No SREs
Disease Category
6 in last year 2032.077 <0.001 0.066 0.979 0.022 <0.001 SREs
Disease Category
5 in last year 152.933 <0.001 0.459 0.992 0.436 <0.001 SREs
Disease Category
4 in last year 614.247 <0.001 0.034 0.364 0.014 <0.001 SREs
Disease Category
3 in last year 13.537 <0.001 0.749 0.906 0.743 <0.001 SREs
Disease Category
2 in last year 1610.239 <0.001 0.064 0.965 0.029 <0.001 SREs
Disease Category
1 in last year 1640.843 <0.001 0.234 1 0.11 <0.001 SREs
Ziprasidone 947.034 <0.001 0.037 0.51 0.014 <0.001 SREs
Vortioxetine 903.45 <0.001 0.008 0 1 <0.001 No SREs
Vilazodone 15.103 <0.001 0.006 0.021 0.004 <0.001 SREs
Trifluoperazine 549.894 <0.001 0.007 0 1 <0.001 No SREs
Trazodone 1068.226 <0.001 0.17 0.919 0.105 <0.001 SREs
Methadone 13.736 <0.001 0.024 0.04 0.017 <0.001 SREs
Meperidine 465.207 <0.001 0.022 0.22 0.006 <0.001 SREs
GENDER 1359.169 <0.001 0.237 0.033 0.624 <0.001 No SREs
Loxapine 422.51 <0.001 0.007 0 1 <0.001 No SREs
Amitriptyline 666.435 <0.001 0.047 0.002 0.259 <0.001 No SREs
Aripiprazole 1651.206 <0.001 0.088 0 0.573 <0.001 No SREs
Asenapine 162.998 <0.001 0.005 0.068 0 <0.001 SREs
Brexpiprazole 1268.74 <0.001 0.004 0 1 <0.001 No SREs
Bupropion 148.547 <0.001 0.109 0.013 0.158 <0.001 No SREs
Buspirone 169.298 <0.001 0.079 0.004 0.132 <0.001 No SREs
Cariprazine 283.31 <0.001 0.004 0 1 <0.001 No SREs
Chlorpheniramine 251.938 <0.001 0.008 0 1 <0.001 No SREs
Chlorpromazine 72.256 <0.001 0.011 0.054 0.005 <0.001 SREs
Clozapine 208.063 <0.001 0.019 0 1 <0.001 No SREs
Desipramine 92.504 <0.001 0.033 0 1 <0.001 No SREs
Desvenlafaxine 113.145 <0.001 0.007 0 0.09 <0.001 No SREs
Dihydroergotamine 1673.55 <0.001 0.008 0 1 <0.001 No SREs
Doxepin 15.421 <0.001 0.029 0.013 0.038 <0.001 No SREs
Dexmethylphenidate 481.108 <0.001 0.004 0 1 <0.001 No SREs
Fluvoxamine 1049.281 <0.001 0.006 0 1 <0.001 No SREs
Lithium 97.967 <0.001 0.075 0.01 0.109 <0.001 No SREs
Escitalopram 14.179 <0.001 0.049 0.024 0.058 <0.001 No SREs
Fentanyl 754.886 <0.001 0.188 0 0.385 <0.001 No SREs
Levomilnacipran 462.413 <0.001 0.009 0 1 <0.001 No SREs
Lamotrigine 341.173 <0.001 0.145 0 0.239 <0.001 No SREs
Flibanserin 21.497 <0.001 0.011 0 1 <0.001 No SREs
Imipramine 863.02 <0.001 0.008 0 1 <0.001 No SREs
Fluoxetine 39.147 <0.001 0.091 0.053 0.119 <0.001 No SREs
Fluphenazine 128.321 <0.001 0.016 0 1 <0.001 No SREs
Haloperidol 450.954 <0.001 0.047 0.32 0.023 <0.001 SREs
Naratriptan 11.737 0.001 0.004 0.019 0.002 0.001246 SREs
Amphetamine 9.941 0.002 0.031 0.018 0.039 0.002455 No SREs
Venlafaxine 8.86 0.003 0.082 0.048 0.089 0.003627 No SREs
Tranylcypromine 8.243 0.004 0.029 0 1 0.004765 No SREs
Disease Category
10 in last year 4.595 0.032 0.027 0.035 0.022 0.037565 SREs
Paliperidone 4.379 0.036 0.007 0.013 0.005 0.041657 SREs
Lurasidone 4.196 0.041 0.032 0.023 0.037 0.046775 No SREs
Zolmitriptan 3.292 0.07 0.002 0.006 0.001 0.07875 N/A
Ropinirole 2.34 0.126 0.016 0.022 0.013 0.139808 N/A
Duloxetine 2.079 0.149 0.069 0.084 0.066 0.162 N/A
Brain Sci. 2020, 10, 784 24 of 27
Table A3. Cont.
T P














Dextromethorphan 2.073 0.15 0.015 0.01 0.017 0.162 N/A
Citalopram 2.027 0.155 0.123 0.094 0.126 0.165197 N/A
Clomipramine 1.945 0.163 0.004 0.01 0.003 0.171468 N/A
Nortriptyline 1.71 0.191 0.012 0.016 0.01 0.198346 N/A
Perphenazine 1.127 0.288 0.017 0.013 0.019 0.295291 N/A
Carbamazepine 0.301 0.584 0.03 0.028 0.032 0.5913 N/A
Eletriptan 0.061 0.804 0.001 0.003 0.001 0.804 N/A
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